Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 2
1947 1
1948 2
1949 1
1965 5
1966 1
1967 2
1968 5
1969 10
1970 7
1971 5
1972 4
1973 5
1974 1
1975 4
1976 5
1977 1
1978 2
1979 3
1980 4
1981 6
1982 1
1983 4
1984 6
1985 7
1986 7
1987 14
1988 14
1989 10
1990 9
1991 16
1992 14
1993 25
1994 8
1995 18
1996 11
1997 19
1998 21
1999 23
2000 25
2001 24
2002 15
2003 20
2004 17
2005 23
2006 21
2007 9
2008 15
2009 17
2010 17
2011 22
2012 37
2013 29
2014 31
2015 38
2016 45
2017 41
2018 55
2019 59
2020 67
2021 108
2022 115
2023 85
2024 83
2025 76
2026 48
2027 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,315 results

Results by year

Filters applied: . Clear all
Page 1
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
Iwamoto Y, Kimura T, Dan K, Iwamoto H, Sanada J, Fushimi Y, Katakura Y, Shimoda M, Yamasaki Y, Nogami Y, Shirakiya Y, Nakanishi S, Mune T, Kaku K, Kaneto H. Iwamoto Y, et al. Among authors: iwamoto h. Diabetes Obes Metab. 2024 Dec;26(12):5982-5994. doi: 10.1111/dom.15972. Epub 2024 Sep 30. Diabetes Obes Metab. 2024. PMID: 39344853
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.
Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, Tomonari T, Sasaki R, Sasaki K, Kakizaki S, Hatanaka T, Iwamoto H, Tanabe N, Yamamoto T, Naganuma A, Shirono T, Kanayama Y, Nishina S, Takayama T, Kobara H, Otsuka M, Kawashima H, Takami T, Kawaguchi T; representing the Hepatology InVestigator Experts in Japan (HIVE-J) Study Group. Shimose S, et al. Among authors: iwamoto h. Hepatol Int. 2025 Aug;19(4):846-855. doi: 10.1007/s12072-025-10781-y. Epub 2025 Feb 28. Hepatol Int. 2025. PMID: 40019708
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.
Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Soldà C, Piscaglia F, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Iavarone M, Di Costanzo G, Marra F, Scartozzi M, Tamburini E, Cabibbo G, Foschi FG, Silletta M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Burgio V, Persano M, Della Corte A, Ratti F, De Cobelli F, Aldrighetti L, Cascinu S, Cucchetti A. Casadei-Gardini A, et al. Among authors: iwamoto h. Eur J Cancer. 2023 Feb;180:9-20. doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Eur J Cancer. 2023. PMID: 36527976 Free article. Clinical Trial.
Serotonin-releasing agents with reduced off-target effects.
Mayer FP, Niello M, Cintulova D, Sideromenos S, Maier J, Li Y, Bulling S, Kudlacek O, Schicker K, Iwamoto H, Deng F, Wan J, Holy M, Katamish R, Sandtner W, Li Y, Pollak DD, Blakely RD, Mihovilovic MD, Baumann MH, Sitte HH. Mayer FP, et al. Among authors: iwamoto h. Mol Psychiatry. 2023 Feb;28(2):722-732. doi: 10.1038/s41380-022-01843-w. Epub 2022 Nov 9. Mol Psychiatry. 2023. PMID: 36352123 Free PMC article.
The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
Yamaguchi K, Takao S, Kanaji N, Hirakawa T, Matsumoto N, Miyazaki K, Okimoto T, Ando C, Higo H, Yanai M, Nagasaki Y, Kurose K, Watanabe M, Oyama K, Toyoda Y, Ono S, Tada S, Iwamoto H, Hattori N. Yamaguchi K, et al. Among authors: iwamoto h. Eur J Cancer. 2025 Aug 26;226:115606. doi: 10.1016/j.ejca.2025.115606. Epub 2025 Jul 5. Eur J Cancer. 2025. PMID: 40639019 Free article.
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma.
Kodama Y, Ueshima K, Moriguchi M, Inaba Y, Yamashita T, Iwamoto H, Ueno M, Ogasawara S, Kuzuya T, Kodama T, Sato Y, Tada T, Tsuchiya K, Nishiofuku H, Yamakado K, Sone M, Ikeda M, Takehara T, Hamano T, Kudo M. Kodama Y, et al. Among authors: iwamoto h. BMC Cancer. 2025 Mar 11;25(1):434. doi: 10.1186/s12885-025-13648-5. BMC Cancer. 2025. PMID: 40069616 Free PMC article.
1,315 results